ClinicalTrials.gg
CompletedNCT04991558INFRAUpdated Mar 7, 2023

Feasibility and Effectiveness of a Coordinated Healthcare Circuit Dedicated to Patients With Handicap

An observational study in Disabilities Physical and Disabilities Mental, sponsored by Groupe Hospitalier Mutualiste de Grenoble. Completed at 1 site in France. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.

Sponsored by Groupe Hospitalier Mutualiste de Grenoble · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
46
Ages
13 Years and older
Sex
All
01

Study summary

France currently has more than 10 million disabled people, including 3 millions who could be better treated. In fact, people with disabilities face many obstacles in accessing care and receiving appropriate support (physical access to certain locations, communication...). Difficulties are also encountered by the healthcare staff, leading to often heterogeneous practices in health establishments.

The INFRA health circuit has been set up at the "Groupe Hospitalier Mutualiste de Grenoble" since June 2018 according to the guidelines published by the French High Authority for Health (HAS) on improving professional practices "Reception, support and organization of care in health establishments for people in situation of handicap "of July 2017. The INFRA nurse collects and anticipates the necessary adaptations for the patient's stay, in conjunction with their caregivers (whether family or institutional). They are an interface with other healthcare professionals to adapt care procedures and protocols (body care, feeding methods, pain management, drug management) to the patient's disability. Before hospitalization and until the patient is discharged, the INFRA nurse transmits to the personnel involved all the information necessary for the proper continuation of care. In addition to legal and regulatory obligations, the INFRA nurse ensures the effective accessibility of the establishment's facilities and premises, and helps maintaining patient autonomy.

The INFRA study is an observational study aimed at assessing the feasibility of the INFRA health circuit and evaluating the benefit for the patients and the healthcare staff.

02

Conditions studied

  • Disabilities Physical
  • Disabilities Mental
03

In context

Lead sponsor

Groupe Hospitalier Mutualiste de Grenoble is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with physical or mental disability, planned for surgical procedure and requiring an adaptation of their healthcare circuit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 13 years old or more
  • Physical or mental disability, according to french law n°2005-102 of February 11th, 2005
  • Requiring an adaptation of the healthcare circuit
  • Indication of a planned surgical procedure

Exclusion criteria

Exclusion Criteria:

  • Outpatient
  • Emergency surgery
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
46 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients who followed the entirety of INFRA circuit

    Time frame: At discharge, assessed up to 4 weeks

Secondary outcomes

  1. Type of pain evaluation scale selected by the INFRA nurse

    Time frame: enrollment

  2. Number of healthcare adaptations implemented during hospitalization

    Time frame: At discharge, assessed up to 4 weeks

  3. Satisfaction of patients and caregivers

    Satisfaction survey answered by patients and caregivers

    Time frame: At discharge, assessed up to 4 weeks

  4. Satisfaction of healthcare staff

    Satisfaction survey answered by healthcare staff

    Time frame: At discharge, assessed up to 4 weeks

07

Study locations

1 site
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble, 38028, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Sep 2022, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2020
First posted
Aug 5, 2021
StartActual
Sep 3, 2020
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Last update
Mar 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04991558
Lead sponsor
Groupe Hospitalier Mutualiste de Grenoble
Responsible party
Sponsor
First posted
Aug 5, 2021
Start date
Sep 3, 2020
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Last update
Mar 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion